AR090605A1 - Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer - Google Patents

Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer

Info

Publication number
AR090605A1
AR090605A1 ARP130101105A ARP130101105A AR090605A1 AR 090605 A1 AR090605 A1 AR 090605A1 AR P130101105 A ARP130101105 A AR P130101105A AR P130101105 A ARP130101105 A AR P130101105A AR 090605 A1 AR090605 A1 AR 090605A1
Authority
AR
Argentina
Prior art keywords
disease
alzheimer
treatment
receiver antagonist
antagonist
Prior art date
Application number
ARP130101105A
Other languages
English (en)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR090605A1 publication Critical patent/AR090605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere a métodos de uso de la 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida en una terapia modificadora de la enfermedad para la enfermedad de Alzheimer, otras tauopatías y enfermedades neurodegenerativas relacionadas.
ARP130101105A 2012-04-06 2013-04-04 Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer AR090605A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305415.7A EP2647377A1 (en) 2012-04-06 2012-04-06 Use of an h3 receptor antagonist for the treatment of alzheimer's disease
US201361792635P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
AR090605A1 true AR090605A1 (es) 2014-11-26

Family

ID=46001073

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101105A AR090605A1 (es) 2012-04-06 2013-04-04 Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer

Country Status (17)

Country Link
US (2) US20150031893A1 (es)
EP (2) EP2647377A1 (es)
JP (1) JP6143842B2 (es)
KR (1) KR20150000490A (es)
CN (1) CN104363911A (es)
AR (1) AR090605A1 (es)
AU (1) AU2013244928B2 (es)
BR (1) BR112014024736A2 (es)
CA (1) CA2868481A1 (es)
ES (1) ES2618924T3 (es)
MX (1) MX354020B (es)
PL (1) PL2833887T3 (es)
RU (1) RU2014144615A (es)
SG (2) SG10201801200PA (es)
TW (1) TW201402119A (es)
UY (1) UY34734A (es)
WO (1) WO2013150150A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
CN105764510A (zh) * 2013-09-09 2016-07-13 赛诺菲 H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
CN114053289B (zh) * 2020-08-06 2023-06-27 北京箭牧科技有限公司 瑞德西韦在制备预防和治疗神经***退行性疾病药物中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1379493A2 (en) 2001-03-23 2004-01-14 Eli Lilly and Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
WO2004037800A1 (en) 2002-10-22 2004-05-06 Glaxo Group Limited Aryloxyalkylamine derivates as h3 receptor ligands
EP1572215B1 (en) 2002-12-20 2009-09-02 Glaxo Group Limited Benzo[d]azepine derivatives for the treatment of neurological disorders
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
DK1615909T3 (da) 2003-04-23 2008-11-17 Glaxo Group Ltd Piperazin-derivater og deres anvendelse til behandling af neurologiske og psykiatriske sygdomme
TW200514781A (en) 2003-07-18 2005-05-01 Glaxo Group Ltd Novel compounds
GB0324159D0 (en) 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
KR100848747B1 (ko) 2004-03-01 2008-07-25 액테리온 파마슈티칼 리미티드 치환된 1,2,3,4-테트라하이드로이소퀴놀린 유도체
GB0408083D0 (en) 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
FR2870846B1 (fr) * 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
PE20060302A1 (es) 2004-06-18 2006-04-08 Glaxo Group Ltd Derivados de benzazepina como antagonistas del receptor h3
GB0418267D0 (en) 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
GB0420831D0 (en) 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
WO2006040192A1 (en) 2004-10-15 2006-04-20 Glaxo Group Limited Pyrrolidine derivatives as histamine receptors ligands
KR20070091007A (ko) 2004-12-07 2007-09-06 글락소 그룹 리미티드 인데닐 유도체 및 신경계 장애의 치료를 위한 이들의 용도
WO2006097691A1 (en) 2005-03-14 2006-09-21 Glaxo Group Limited Fused thiazole derivatives having affinity for the histamine h3 receptor
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
EP1790646A1 (fr) 2005-11-24 2007-05-30 Sanofi-Aventis Derives de Isoquinoline et Benzo[h]Isoquinoline, leur preparation et leur utilisation en thérapeutique en tant qu'antagonistes du recepteur de l'histamine H3.
ATE509636T1 (de) 2006-06-23 2011-06-15 Esteve Labor Dr Kombination aus einem cholinesterase-hemmer und einer verbindung mit 5-ht6-rezeptor-affinität
CL2008000597A1 (es) 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
US20090170869A1 (en) 2007-09-06 2009-07-02 Desmond John Best Piperazine derivative having affinity for the histamine h3 receptor
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
EP2328587A1 (en) 2008-08-29 2011-06-08 Glaxo Group Limited Dosage form comprising 1-isopropyl-4-{ [4-(tetrahydro-2h-pyran- 4-yloxy)phenyl]carbonyl}hexahydro-1h-1,4-diazepine or a salt thereof
WO2010026113A1 (en) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
MX2011012824A (es) 2009-06-26 2012-01-27 Sanofi Sa Nuevas sales de fumarato de un antagonista del receptor de histamina h3.
AR077859A1 (es) 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
WO2011051423A1 (en) 2009-11-02 2011-05-05 Glaxo Group Limited Treatment or prophylaxis of dementia, neurodegenerative disorders, schizophrenia, adhd, somnolence or epilepsy
FR2976286B1 (fr) 2011-06-08 2013-05-24 Servier Lab 4-{3-[trans-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide, son procede de preparation et les compositions pharmaceutiques qui le contiennent
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
EP2745876A1 (en) 2012-12-21 2014-06-25 Prous Institute for Biomedical Research, S.A. Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
CN105764510A (zh) * 2013-09-09 2016-07-13 赛诺菲 H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途

Also Published As

Publication number Publication date
BR112014024736A2 (pt) 2017-07-11
CN104363911A (zh) 2015-02-18
EP2833887B1 (en) 2016-12-28
RU2014144615A (ru) 2016-05-27
SG11201406093VA (en) 2014-10-30
EP2647377A1 (en) 2013-10-09
JP2015516963A (ja) 2015-06-18
TW201402119A (zh) 2014-01-16
ES2618924T3 (es) 2017-06-22
CA2868481A1 (en) 2013-10-10
AU2013244928A1 (en) 2014-10-30
MX354020B (es) 2018-02-08
SG10201801200PA (en) 2018-04-27
MX2014011992A (es) 2015-05-08
UY34734A (es) 2013-11-29
WO2013150150A1 (en) 2013-10-10
PL2833887T3 (pl) 2017-06-30
KR20150000490A (ko) 2015-01-02
AU2013244928B2 (en) 2017-08-10
EP2833887A1 (en) 2015-02-11
JP6143842B2 (ja) 2017-06-07
US20160101099A1 (en) 2016-04-14
US20150031893A1 (en) 2015-01-29
US9789102B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
IL268974B (en) Labeled inhibitors of prostate-specific membrane antigen (psma), their use as imaging agents and as pharmaceutical agents for the treatment of prostate cancer
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
UA107827C2 (en) Antibody cd40
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
CO7200273A2 (es) Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
ZA201700671B (en) Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CL2013002053A1 (es) Compuestos derivados de heterociclicos, antagonistas del receptor de glucagon; composicion farmaceutica que lo comprende y su uso en el tratamiento de diabetes y enfermedades metabolicas. pct
CL2017001756A1 (es) Régimen de dosificación para antagonistas de madcam.
PH12016502353A1 (en) Pharmaceutical composition
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
CL2017000050A1 (es) Terapia de combinación para el cáncer
CL2012001293A1 (es) Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer
TW201613577A (en) Pharmaceutical combinations
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
EA201590823A1 (ru) 6-((s)-1-{1-[5-(2-гидроксиэтокси)пиридин-2-ил]-1h-пиразол-3-ил}этил)-3h-1,3-бензотиазол-2-он в качестве антагониста tarp-гамма 8-зависимого ampa-рецептора
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
AR090605A1 (es) Un antagonista del receptor h3 para uso en el tratamiento de la enfermedad de alzheimer
DK3402537T3 (da) Kvantitativ PET-afbildning af vævsfaktorekspression under anvendelse af 18-F mærket, aktiv positions-inhiberet faktor VII
CO6480943A2 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
IT201600128780A1 (it) Bastoncino igienico per la cura della persona,in particolare per l’igiene dell’orecchio
EA201491226A1 (ru) НОВОЕ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ p75

Legal Events

Date Code Title Description
FB Suspension of granting procedure